Tri Locum Partners as of Sept. 30, 2022
Portfolio Holdings for Tri Locum Partners
Tri Locum Partners holds 41 positions in its portfolio as reported in the September 2022 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Eli Lilly & Co. (LLY) | 9.3 | $34M | 105k | 323.35 | |
| Biogen Idec (BIIB) | 6.6 | $24M | 91k | 267.00 | |
| Argenx Se Sponsored Adr (ARGX) | 6.2 | $23M | 64k | 353.05 | |
| Neurocrine Biosciences (NBIX) | 5.7 | $21M | 196k | 106.21 | |
| Regeneron Pharmaceuticals (REGN) | 5.7 | $21M | 30k | 688.86 | |
| Catalent (CTLT) | 4.7 | $17M | 235k | 72.36 | |
| Guardant Health (GH) | 4.2 | $15M | 286k | 53.83 | |
| Jazz Pharmaceuticals Shs Usd (JAZZ) | 3.9 | $14M | 107k | 133.29 | |
| Edwards Lifesciences (EW) | 3.9 | $14M | 171k | 82.63 | |
| Stevanato Group S P A Ord Shs (STVN) | 3.6 | $13M | 772k | 16.94 | |
| Cassava Sciences Call Option (SAVA) | 3.3 | $12M | 289k | 41.82 | |
| GSK Sponsored Adr | 3.3 | $12M | 410k | 29.43 | |
| Bausch Plus Lomb Corp Common Shares (BLCO) | 2.9 | $11M | 701k | 15.34 | |
| Mirati Therapeutics | 2.9 | $11M | 152k | 69.84 | |
| Sarepta Therapeutics (SRPT) | 2.9 | $11M | 95k | 110.53 | |
| The Beauty Health Company Com Cl A (SKIN) | 2.7 | $9.7M | 825k | 11.79 | |
| Allogene Therapeutics (ALLO) | 2.3 | $8.5M | 784k | 10.80 | |
| Prometheus Biosciences | 2.0 | $7.3M | 124k | 59.01 | |
| Maravai Lifesciences Hldgs I Com Cl A (MRVI) | 2.0 | $7.2M | 281k | 25.53 | |
| Akero Therapeutics (AKRO) | 2.0 | $7.1M | 209k | 34.05 | |
| Celldex Therapeutics Com New (CLDX) | 1.8 | $6.7M | 239k | 28.11 | |
| Coherus Biosciences (CHRS) | 1.7 | $6.1M | 637k | 9.61 | |
| Kezar Life Sciences (KZR) | 1.7 | $6.1M | 710k | 8.61 | |
| Astria Therapeutics (ATXS) | 1.6 | $5.7M | 632k | 9.04 | |
| Natera (NTRA) | 1.6 | $5.7M | 130k | 43.82 | |
| Teva Pharmaceutical Inds Sponsored Ads (TEVA) | 1.5 | $5.5M | 684k | 8.07 | |
| Xenon Pharmaceuticals (XENE) | 1.3 | $4.8M | 134k | 36.10 | |
| Ventyx Biosciences (VTYX) | 1.2 | $4.4M | 125k | 34.91 | |
| X4 Pharmaceuticals (XFOR) | 1.2 | $4.3M | 2.5M | 1.71 | |
| Inspire Med Sys (INSP) | 1.1 | $4.2M | 23k | 177.39 | |
| Iveric Bio | 0.9 | $3.4M | 191k | 17.94 | |
| Beam Therapeutics (BEAM) | 0.7 | $2.6M | 54k | 47.64 | |
| Crispr Therapeutics Namen Akt (CRSP) | 0.7 | $2.4M | 37k | 65.36 | |
| Bellus Health Com New | 0.6 | $2.3M | 215k | 10.56 | |
| Altimmune Com New (ALT) | 0.6 | $2.0M | 157k | 12.77 | |
| Vaxcyte (PCVX) | 0.5 | $1.9M | 79k | 24.00 | |
| Protagonist Therapeutics Call Option (PTGX) | 0.5 | $1.7M | 200k | 8.43 | |
| Fibrogen (FGEN) | 0.3 | $967k | 74k | 13.01 | |
| Arcellx Common Stock (ACLX) | 0.2 | $804k | 43k | 18.77 | |
| Leap Therapeutics | 0.2 | $626k | 712k | 0.88 | |
| Femasys (FEMY) | 0.0 | $120k | 107k | 1.13 |
